Prevention, Diagnosis & Treatment
Bayer is committed to meeting the needs of patients in our therapeutic areas of focus, including cardiovascular disease, pulmonary hypertension, hematology, oncology, multiple sclerosis and women’s healthcare. Bayer’s brands treat and prevent conditions to improve quality of life. (Bayer’s U.S. R&D program supports some of Bayer’s more broad global focus areas).
Bayer’s US oncology expertise is deep and wide. Bayer currently markets treatments for Prostate, colon, GIST, liver, and thyroid cancers in the U.S. Some were the first treatment to market, and some remain the only approved treatment or the only drug to show overall survival benefit for its indication.
Empowering women to make a conscious decision on whether and when to have children has decisively strengthened women’s roles in society. Thanks to modern hormonal contraceptives ranging from pills to intrauterine devices, couples today can better plan their families and experience sexuality with the security in knowing that pregnancy is prevented.
Bayer has numerous compounds in various stages of development for hemophilia A and other blood and bleeding disorders. Together, these compounds show our commitment to research and development for these conditions.
As the first company to offer an efficacious, innovative treatment for multiple sclerosis in the U.S., Bayer is a pioneer with a long-term commitment to patients living with this challenging disease. Besides being the first company to offer an efficacious, innovative treatment for MS, Bayer continuously invests in the new offerings to support patients with MS and their differing needs. Bayer was the first company to offer nursing services to patients, providing education, training, and emotional support, and Bayer is continuing to identify new and innovative ways to better serve patients and improve their daily lives with MS.
Bayer’s history is steeped in cardiovascular care, and Bayer continues to develop products that may be of benefit for patients with various cardiovascular challenges. Kidney function - or malfunction, in the case of Chronic Kidney Disease - can have a detrimental effect on the cardiovascular system, so Bayer is exploring solutions that impact kidney health, as a holistic means to an end.
In the area of Pulmonary Hypertension, scientists at Bayer discovered direct stimulators of soluble guanylate cyclase stimulators (sGC), a new way to widen the blood vessels, to lower blood pressure in the lungs and relieve the heart. Bayer’s compound became first member of this distinct class of medicines and the first drug therapy to be approved in two forms of pulmonary hypertension. Its distinct mode of action has the potential to overcome a number of limitations of previously approved treatments for pulmonary arterial hypertension (PAH) and it is the first drug therapy to become available for another type of PH, inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment.
Being diagnosed through radiology is often the first step in a patient’s journey. These helpful diagnostic tools give healthcare professionals control to properly identify an ailment and know if treatment is working. Bayer provides radiologists with a portfolio of diagnostic imaging products and services along the radiology workflow and engages collaboratively with original equipment manufacturers (OEMs) of diagnostic imaging scanners and healthcare IT partners.
Bayer has been committed to radiology for more than 100 years and continues to partner with radiologists to guide diagnostic care. Explore our radiology solutions.
See Bayer’s US brands